ANAVEX LIFE SCIENCES CORP. Cash and Restricted Cash
ANAVEX LIFE SCIENCES CORP. (AVXL) had Cash and Restricted Cash of $118.33 million as of 2026-06-30, per its 10-Q filed 2026-08-28.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-28
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $118.33M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $127.42M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $131.75M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $102.58M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $118.33M 10-Q · filed 2026-08-28 | |
| 2026-03-31 | $127.42M 10-Q · filed 2026-08-28 | |
| 2025-12-31 | $131.75M 10-Q · filed 2026-02-09 | |
| 2025-09-30 | $102.58M 10-K/A · filed 2026-08-28 | |
| 2025-06-30 | $101.16M 10-Q · filed 2026-08-28 | |
| 2025-03-31 | $115.77M 10-Q · filed 2026-08-28 | |
| 2024-12-31 | $120.78M 10-Q · filed 2026-02-09 | |
| 2024-09-30 | $132.19M 10-K/A · filed 2026-08-28 | |
| 2024-06-30 | $138.76M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $139.39M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $143.76M 10-Q · filed 2025-02-12 | |
| 2023-09-30 | $151.02M 10-K/A · filed 2026-08-28 | |
| 2023-06-30 | $154.82M 10-Q · filed 2024-08-06 | $154.82M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $153.47M 10-Q · filed 2024-05-09 | $153.47M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $143.62M 10-Q · filed 2024-02-07 | $143.62M 10-Q · filed 2023-02-07 |
| 2022-09-30 | $149.16M 10-K/A · filed 2026-08-28 | $149.16M 10-Q · filed 2023-02-07 |
| 2022-06-30 | $153.20M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $153.34M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $151.15M 10-Q · filed 2023-02-07 | |
| 2021-09-30 | $152.11M 10-K · filed 2023-11-27 | $152.11M 10-Q · filed 2022-05-10 |
| 2021-06-30 | $157.56M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $75.86M 10-Q · filed 2022-05-10 | |
| 2020-09-30 | $29.25M 10-K · filed 2023-11-27 | $29.25M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |